Kaal A - Search Results

1

Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment.

Kaal A, Orskov H, Nielsen S, Pedroncelli AM, Lancranjan I, Marbach P, Weeke J. Kaal A, et al. Eur J Endocrinol. 2000 Sep;143(3):353-61. doi: 10.1530/eje.0.1430353. Eur J Endocrinol. 2000. PMID: 11022177 Clinical Trial.

2

Long-term efficacy and tolerability of octreotide treatment in acromegaly.

Christensen SE, Weeke J, Orskov H, Kaal A, Lund E, Jørgensen J, Harris AG. Christensen SE, et al. Among authors: kaal a. Metabolism. 1992 Sep;41(9 Suppl 2):44-50. doi: 10.1016/0026-0495(92)90030-e. Metabolism. 1992. PMID: 1518433 Clinical Trial.

3

A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly.

Weeke J, Christensen SE, Orskov H, Kaal A, Pedersen MM, Illum P, Harris AG. Weeke J, et al. Among authors: kaal a. J Clin Endocrinol Metab. 1992 Jul;75(1):163-9. doi: 10.1210/jcem.75.1.1619006. J Clin Endocrinol Metab. 1992. PMID: 1619006 Clinical Trial.

4

Effects of antibodies against octreotide in two patients with acromegaly.

Orskov H, Christensen SE, Weeke J, Kaal A, Harris AG. Orskov H, et al. Among authors: kaal a. Clin Endocrinol (Oxf). 1991 May;34(5):395-8. doi: 10.1111/j.1365-2265.1991.tb00311.x. Clin Endocrinol (Oxf). 1991. PMID: 2060149

5

Growth hormone binding protein and growth hormone availability in acromegalic patients treated with long-acting octreotide (Sandostatin-LAR).

Fisker S, Kaal A, Montini M, Pedroncelli A, Pagani G, Orskov H. Fisker S, et al. Among authors: kaal a. Eur J Endocrinol. 1997 Jan;136(1):61-6. doi: 10.1530/eje.0.1360061. Eur J Endocrinol. 1997. PMID: 9037128 Clinical Trial.

6

Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency.

Skjaerbaek C, Frystyk J, Kaal A, Laursen T, Møller J, Weeke J, Jørgensen JO, Sandahl Christiansen J, Orskov H. Skjaerbaek C, et al. Among authors: kaal a. Clin Endocrinol (Oxf). 2000 Jan;52(1):25-33. doi: 10.1046/j.1365-2265.2000.00876.x. Clin Endocrinol (Oxf). 2000. PMID: 10651750 Clinical Trial.

7

SMS 201-995 and thyroid function in acromegaly: acute, intermediate and long-term effects.

Christensen SE, Weeke J, Kaal A, Harris AG, Orskov H. Christensen SE, et al. Among authors: kaal a. Horm Metab Res. 1992 May;24(5):237-9. doi: 10.1055/s-2007-1003301. Horm Metab Res. 1992. PMID: 1398464

8

Preliminary results with Sandostatin nasal powder in acromegalic patients.

Harris AG, Weeke J, Christensen SE, Kaal A, Illum P, Orskov H. Harris AG, et al. Among authors: kaal a. Metabolism. 1992 Sep;41(9 Suppl 2):72-5. doi: 10.1016/0026-0495(92)90035-9. Metabolism. 1992. PMID: 1518437

9

No effect of growth hormone on serum insulin-like growth factor binding protein-3 proteolysis.

Skjaerbaek C, Kaal A, Møller J, Vahl N, Weeke J, Orskov H, Flyvbjerg A. Skjaerbaek C, et al. Among authors: kaal a. J Clin Endocrinol Metab. 1998 Apr;83(4):1206-10. doi: 10.1210/jcem.83.4.4686. J Clin Endocrinol Metab. 1998. PMID: 9543142

10

[Long-term treatment with octreotide of patients with acromegaly].

Weeke J, Orskov H, Christensen SE, Kaal A, Skjaerbaek C, Illum P, Jørgensen J, Lund E, Haubek A, Poulsen JH. Weeke J, et al. Among authors: kaal a. Ugeskr Laeger. 1993 Aug 23;155(34):2592-8. Ugeskr Laeger. 1993. PMID: 8212364 Clinical Trial. Danish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters